Skip to main content
RDNTRadNet, Inc.Sell5.6·$73.54
SellModerate Confidence
Investment thesis

RadNet operates in the healthcare diagnostics sector with 22% revenue growth and 57% analyst upside, but its quality score of 2.1 out of 10 reflects zero net margin, weak return on assets, no competitive moat, and mixed earnings execution — leaving this as a growth story that has not yet translated into business quality sufficient to meet minimum investment thresholds.

Thesis pillars

  • Quality Below Minimum Floor→Stable
  • Revenue Growth Momentum Recovery↑Improving
  • Mixed Earnings Execution↑Improving
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Mar 2, 2026

Full reasoning →

Open full analysis

RadNet, Inc. (RDNT) Stock Analysis

Breakout setup

SellVALUE-TRAP 2/5GrowthModerate Confidence

Healthcare · Diagnostics & Research

Earnings in 7 days (2026-11-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $73.54: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 14%; Below-average business quality.

RadNet operates 418 outpatient diagnostic imaging centers across nine US states, making it the largest operator by number of centers and revenue. Revenue comes from imaging services billed to a diverse payor mix including commercial insurers, Medicare/Medicaid, and capitation... Read more

$73.54+11.9% A.UpsideScore 5.6/10#12 of 32 Diagnostics & Research
QualityF-score5 / 9FCF yield2.73%
Stop $68.98Analyst target $82.32(−13% haircut)A.R:R 1.2:1
Analyst consensus$94.63+28.7%8 analysts
$82.32Analyst target
$73.54price
$94.63mean
$105

Sell if holding. Engine safety override at $73.54: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 14%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Score 5.6/10, moderate confidence.

Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: aggressive.

10-K grounded · weekly refresh

About RadNet, Inc.

About RadNet, Inc.

RadNet's 418 freestanding outpatient diagnostic imaging centers across nine states — Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, Texas, and Virginia — make it the largest such operator in the United States by both location count and annual imaging revenue. The Digital Health segment held 22 FDA clearances and 15 CE marks across its AI-enabled radiology software portfolio as of December 31, 2025, and the 2025 acquisition of ICAD Inc. added approximately 1,500 customers and breast cancer detection AI capabilities.

RadNet earns imaging service revenue from a diversified payor mix including commercial insurance companies, managed care capitation arrangements, and government programs such as Medicare and Medicaid. Capitation contracts accounted for approximately 6% of total net revenue in fiscal 2025, under which payors pay fixed per-patient-per-month fees and the company assumes utilization risk for the covered population. The Digital Health segment generates software revenue from over 2,000 global customers through enterprise radiology platforms including RIS/PACS systems, the DeepHealth OS operating system, and AI applications for mammography, lung, prostate, and ultrasound image interpretation. RadNet competes against independent imaging operators, private equity-backed chains, smaller regional operators, and hospital systems, differentiating through multi-modality centers that offer MRI, CT, PET, nuclear medicine, mammography, ultrasound, X-ray, and fluoroscopy at a single location.

Show full overview

RadNet's reimbursement structure subjects the company to ongoing CMS policy risk: on October 30, 2025, the Centers for Medicare & Medicaid Services released the calendar year 2026 Medicare Physician Fee Schedule final rule governing RadNet's payments. Medicare and Medicaid represent significant payor sources, and the 10-K notes that budget deficits during high-unemployment periods could reduce federal and state spending on healthcare programs. California-specific minimum wage increases enacted in 2024 raised compensation costs starting in 2025 for a state hosting more than 100 of RadNet's centers, while multi-year contracted reimbursement rates may not fully offset those labor cost increases.

See also: Healthcare · Diagnostics & Research

From RadNet, Inc.'s most recent 10-K filing, extracted June 11, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-10-29

Recent Developments — RadNet, Inc.

Generated 2026-10-29T13:34:03Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Nov 5, 20267d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (2.6 < 4.0)
Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow

Key Metrics

P/E (TTM)—
P/E (Fwd)89.7
Mkt Cap$5.8B
EV/EBITDA27.3
Profit Mgn-0.9%
ROE1.5%
Rev Growth25.0%
Beta1.41
DividendNone
Rating analysts14

Quality Signals

Piotroski F5/9

Options Flow

P/C0.17bullish
IV69%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Unprofitable operations — net margin -0.9%. Quality floor flags this regardless of sector context.static

Gross Margin
0.0
Net Margin
0.0
Roe
0.5
Roa
1.1
Operating Margin
3.2
Moat
4.9
Current Ratio
5.5
Piotroski F
5.6
No competitive moatQuality concerns

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.0
Support Resistance
1.7
52w Position
7.1
GatesA.R:R 1.2 < 1.5@spotEARNINGS PROXIMITY 7d<=7dMomentum 7.6>=5.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive
RSI
66 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $66.23Resistance $75.02

Price Targets

$69
$82
A.Upside+11.9%
A.R:R1.2:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (2.6 < 4.0)
! Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
! asymmetry at 1.2 (below the engine's 1.5 threshold)@spot

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-11-05 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is RDNT stock a buy right now?

Sell if holding. Engine safety override at $73.54: Quality below floor (2.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: High short interest: 14%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Prior stop was $68.98. Score 5.6/10, moderate confidence.

What is the RDNT stock price target?

Analyst target: $82.32 (+11.9% upside). Prior stop was $68.98. Stop-loss: $68.98.

What are the risks of investing in RDNT?

Quality below floor (2.6 < 4.0); Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow.

Is RDNT overvalued or undervalued?

RadNet, Inc. trades at a P/E of N/A (forward 89.7). TrendMatrix value score: 5.1/10. Verdict: Sell.

What do analysts say about RDNT?

14 analysts cover RDNT with a consensus score of 4.3/5. Average price target: $95.

What does RadNet, Inc. do?RadNet operates 418 outpatient diagnostic imaging centers across nine US states, making it the largest operator by...

RadNet operates 418 outpatient diagnostic imaging centers across nine US states, making it the largest operator by number of centers and revenue. Revenue comes from imaging services billed to a diverse payor mix including commercial insurers, Medicare/Medicaid, and capitation arrangements (~6% of net revenue in 2025). A Digital Health segment develops and sells AI-enabled radiology software and RIS/PACS systems to 2,000+ customers globally.

Related stocks: NEO (NeoGenomics, Inc.) · VCYT (Veracyte, Inc.) · CDNA (CareDx, Inc.) · SHC (Sotera Health Company) · CSTL (Castle Biosciences, Inc.)
Home › Stocks › RDNT

Latest news

Latest News

Fiscal.ai2h agoEarnings
Fiscal.ai3d agoMerger Acquisition
Benzinga3d agoMerger Acquisition
Benzinga16d ago
Benzinga62d agoAnalyst
Benzinga79d ago
Benzinga80d ago
Benzinga91d agoFda Decision
Benzinga92d ago
Benzinga112d ago
Benzinga126d agoFda Decision
Benzinga141d agoProduct
Benzinga148d ago
Benzinga162d agoAnalyst
Benzinga171d ago
Benzinga171d agoEarnings